Start antiarrhythmic medicine safely at home with an automated heart-monitoring kit
Official title: Novel, automated mobile heart rhythm analysis technology to start antiarrhythmic medications safely at home
Funded at Safebeat Rx INC. · NIH-11141594 · Data updated 2026-11-12
A home monitoring kit uses automated ECG and wearable defibrillator technology to help people with atrial fibrillation begin antiarrhythmic medicines without a three-day hospital stay.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Safebeat Rx INC. NIH-funded |
| Lab location | 1 site (Carson, UNITED STATES) |
| Project start | July 19, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $977,252 |
| NIH project number | 5R44HL167294-02 |
| Project ID | NIH-11141594 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with atrial fibrillation who are candidates for starting oral antiarrhythmic medications and who can use a smartphone and wear home monitoring devices are the ideal candidates.
✕Less likely to help
People with high-risk heart conditions, recent unstable cardiac disease, inability to use or wear the devices, or without reliable cell/internet service are unlikely to benefit from the at-home approach.
What this research studies
You would receive a SafeBeat Kit that combines a mobile ECG device, continuous mobile cardiac telemetry, and a wearable defibrillator with proprietary software that automatically measures and tracks QTc and other rhythm changes. The system uses machine learning to automate QTc readings from ECGs and sends alerts to clinicians if dangerous changes appear. During the program you wear the devices while starting antiarrhythmic medication so clinicians can monitor you remotely instead of admitting you to the hospital. The goal is to make initiation of these medicines safer and more accessible, especially for patients in rural or underserved areas.
Why it matters
Potential benefit: If successful, this could let many people with atrial fibrillation start life-prolonging antiarrhythmic drugs at home and avoid a multi-day hospital admission.
How similar studies have gone: Prior phase-I equivalent work from the sponsor produced a machine-learning algorithm that automates QTc measurement, but using a combined home monitoring kit to start antiarrhythmic drugs is a novel approach not yet proven in large trials.
Where this research is happening
-
Safebeat Rx INC.
Carson, United States Active
Researchers
- Principal investigator: Navara, Rachita — Safebeat Rx INC.
- Study coordinator: Navara, Rachita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.